MLN8237

1028486-01-2

A potent, selective and orally bioavailable Aurora A Kinase inhibitor with more than 200-fold selectivity against Aurora B Kinase, currently in clinical trial

Store at 0° C (short term), -20° C (long term), desiccated

HPLC, ¹HNMR and Quantitative Elemental Analysis

1. Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1; 878(25):2369-73

2. M. G. Manfredi, et al, Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays, Clin Cancer Res, Dec 15, 2011, 17; 7614

3. Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, Mueller I, Savory WJ, Williams DH, Eyers PA. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol. 2010 Jun 18; 5(6):563-76.